GR
Gangadharan Raveendran
About Gangadharan Raveendran
Gangadharan Raveendran has 5 years in corporate governance. Holds Additional Director role. Currently with 1 company, including Larash Technologies Private Limited. Formerly with 2 companies, such as Sushphani Ventures Private Limited and 360D Healthcare Services Private Limited. Engaged in Technology, General Business and more. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Larash Technologies Private Limited
U60100KA2017PTC105656
|
Additional Director | 12 Apr 2022 | 2017 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Sushphani Ventures Private Limited
U85300KA2021PTC148235
|
Director | 07 Jun 2021 | 2021 | Active |
360D Healthcare Services Private Limited
U72900KA2020PTC141211
|
Director | 28 Mar 2021 | 2020 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Gangadharan Raveendran
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gangadharan Raveendran
Gangadharan Raveendran has 5 years in corporate governance. Holds Additional Director role. Currently with 1 company, including Larash Technologies Private Limited. Formerly with 2 companies, such as Sushphani Ventures Private Limited and 360D Healthcare Services Private Limited. Engaged in Technology, General Business and more. Contributes to corporate operations.
Gangadharan Raveendran is associated with 1 company as Additional Director.
Gangadharan Raveendran has expertise in Technology, General Business and other sectors.
Gangadharan Raveendran has 5 years in corporate governance.